Faes Farma, S.a. · BME:FAE
Faes Farma — Investor Day (April 2025)
43 slides from Faes Farma's investor day presentation, Apr 22, 2025
Slide 1: Capital Markets Day Faes Farma 2025
CAPITAL MARKETS DAY FAES FARMA 2025 Madrid 22/04/2025
Slide 2: Agenda
AGENDA 1/ 2/ Video and Mariano Ucar Strong Eduardo Introduction President of Faes Farma foundations: Recoder CEO of Faes Farma 2014-2024 3/ 4/ Strategic Plan 2025-2030: Q&A Transforming the future 01/ 02/ Culture, organisation Faes Farma 2030: and ambition focus on 4 strategic pillars Eduardo José L
Slide 3: Slide 3
Slide 4: Solid foundations: 2014-2024
Solid foundations: 2014-2024 Eduardo Recoder CEO of Faes Farma
Slide 5: Global Vision and Leadership
Global Vision and Leadership Eduardo Recoder de la Cuadra, Faes Farma's new CEO An executive with more than Now, at the helm of Faes 20 years of global experience Farma, his leadership will be in the pharmaceutical key to accelerating growth, industry, he has led key boosting international markets i
Slide 6: Faes Farma, a history of solid foundations
Faes Farma, a history of solid foundations... 1933 Consolidation in new markets and geographies, transforming from a Reinforcing the commitment to LATAM 2024 92 years of national company to a global Consolidation of business ...and with room for history... company. with organic and inorganic further
Slide 7: ...with a strong growth trajectory
...with a strong growth trajectory Revenue EBITDA Net profit 2024 510 M€ 2024 129 M€ 2024 111 M€ 2014 198 M€ 2014 42 M€ 2014 25 M€ x2,5 x3 x4,4 Partners Revenues rest of the world Evolution of revenues by geography in %. 2014 2024 2024 37 2024 291 M€ 43% 43% 2014 5 2014 85 M€ 57% 57% (+14 p.p.) X7,4
Slide 8: Faes Farma at a glance today: Top 3
Faes Farma at a glance today: A global business, consolidated and ready for further growth +130 Revenues by business Revenues by geography Employees countries with presence 10% 43% 48% Animal nutrition Spain Spain 8 90% Farma 57% Rest of the world 52% International production plants 11 subsidiaries
Slide 9: Strategic Plan 2025-2030: transforming the future
3/ Strategic Plan 2025-2030: transforming the future 01/ 02/ Culture, organisation and ambition Focus on 4 strategic pillars Eduardo Recoder José Luís Díaz Alberto Fernández Juan Veiga CEO Chief International Business Chief Marketing and Portfolio Head of Transformation Office Officer Strategy Offic
Slide 10: Culture, organisation and ambition
Strategic Plan 2025-2030: transforming the future 01// Culture, organisation and ambition Madrid 22/04/2025
Slide 11: A new culture based on a renewed corporate purpose
A new culture: based on a renewed corporate purpose Bringing together passion, science and innovation to transform people's health Our values The patient, our priority We are innovative We care for people and the environment Vision Mission To be a leading We develop and deliver Excellence that trans
Slide 12: A new organisation
A new organisation, More agile, integrated and strategic + TALENT Balancing internal and external talent with attraction and retention of key profiles Presidency Mariano Ucar Non.Executive Chairman + GLOBAL Mariana Cross-cutting positions for an Soroa international organisation Chief GRC & Internal
Slide 13: The new ambition in figures
The new ambition in figures Outlook 2024 - 2030 (M€) Income Revenue +11/12% CAGR ~1.000 / Organic growth of +8/10% in 2025, driven by strong performance 815-845 of international pharma sales (excl. Edol) 510 +8/10% / CAGR 2024-30 estimated at +11/12% including M&A, of which +8/9% corresponds to orga
Slide 14: Focus on 4 strategic pillars
Strategic Plan 2025-2030: transforming the future 02// Focus on 4 strategic pillars Madrid 22/04/2025
Slide 15: New plan 2025-2030: based on key pillars for growth
New plan 2025-2030: based on 4 key pillars for growth To be recognised as the best global Spanish pharmaceutical company Accelerate the Leading from Achieving commercial Promoting a positive and operational impact on our culture growth science excellence and environment / Growing organically in exis
Slide 16: New plan 2025-2030: based on key pillars for growth
New plan 2025-2030: based on 4 key pillars for growth To be recognised as the best global Spanish pharmaceutical company Accelerate the Leading from Achieving commercial Promoting a positive and operational impact on our culture growth science excellence and environment / Growing organically in exis
Slide 17: Ambition 2030: double our sales
ACCELERATING GROWTH Ambition 2030: double our sales Growth levers Revenues by business area Faes Farma in M€ /01 +11-12% Roadmap for organic growth of the Pharma business, CAGR based on current portfolio, territories and pipeline +8-9% CAGR 160-180 ~1.000 /02 65-75 815-845 FARM Faes (Animal Nutritio
Slide 18: Organic growth driven mainly by international markets
ACCELERATING GROWTH Pharma Organic growth driven mainly by international markets Growth levers Revenues of Pharma in M€ TOTAL: 7-9% CAGR Iberia* 6-7% CAGR 300-310 /01 208 To grow in Iberia by incorporating innovations to the current portfolio together with the integration of Edol, key to enrich the
Slide 19: Business in Iberia strengthened by innovation and continuous development
ACCELERATING GROWTH Pharma / Iberia Business in Iberia strengthened by innovation and continuous development Growth levers Iberia Revenues in M€ /01 +6-7% Continue organic growth by consolidating the current portfolio and CAGR leveraging our innovation in key products. 55-60* 300-310 /02 40-45 Edol
Slide 20: Expansion drive to double international revenues
ACCELERATING GROWTH Pharma / International Expansion drive to double international revenues Growth levers International Revenues* in M€ /01 +12-14% CAGR Strengthen operations in key LATAM markets with the ambition of becoming the #1 Spanish pharmaceutical company **. 23 14-24 295-305 304 20 115 /02
Slide 21: Diversification of licences to reduce risks and create growth opportunities
ACCELERATING GROWTH Pharma / Licensing Diversification of licences to reduce risks and create growth opportunities Growth levers Evolution of licensing agreement revenues, M€. /01 Impact Japan and Canada Recovery record Projected new revenues from already signed agreements offsetting levels licences
Slide 22: Strong focus on vertical integration and expansion of production capacity
ACCELERATING GROWTH FARM Faes Strong focus on vertical integration and expansion of production capacity Growth levers /01 - Internationalisation /02 - Diversification Expand existing markets and Diversify towards nutrition for other enter emerging markets with new species and nutraceuticals to reduc
Slide 23: Laboratorios Edol, a step forward in ophthalmology
ACCELERATING GROWTH M&A Laboratorios Edol, a step forward for Faes Farma in ophthalmology Edol brings a portfolio with high internationalisation potential and strong growth performance Evolution of Edol's sales, M€. Advantages of the integration of Edol for Faes Farma... / Positioning in ophthalmolo
Slide 24: Strategic acquisitions for short and medium-term growth
ACCELERATING GROWTH M&A Strategic acquisitions for short and medium-term growth M&A: target company profile / Products with potential for innovation and LCM*. Portfolio / Innovative products in advanced stages of development / Therapeutic areas that maximise synergies Therapeutic Areas / Therapeutic
Slide 25: New plan 2025-2030: based on key levers for growth
New plan 2025-2030: based on 4 key levers for growth To be recognised as the best global Spanish pharmaceutical company Accelerate the Leading from Achieving commercial Promoting a positive and operational impact on our culture growth science excellence and environment / Growing organically in exist
Slide 26: Driving forward the new era of R&D&I
LEADING FROM SCIENCE Driving forward the new era of R&D&I 2024 2025-2030 / Boosting bilastine in paediatrics. +20 active With key milestones reached in 15 Strategic / Strengthening the calcifediol franchise with weekly formulations and osteoporosis-focused developments / Marketing the broadest range
Slide 27: 4 R&D&I platforms
LEADING FROM SCIENCE 4 R&D&I platforms New New development development area area Research Scouting for external Innovation Incremental new molecules opportunities high-value innovation Innovation New molecules for Acceleration of the pipeline in Accelerated pipeline Life cycle extension and inflamma
Slide 28: Strong portfolio and direction
LEADING FROM SCIENCE Strong portfolio and direction Revenue 2024 M€ Strategic Therapeutic Areas Main molecules (vs. 2023 %) Incremental innovation of the three main molecules in Faes Farma's portfolio will contribute ~35% of the Allergies Bilastine 125,6 (+3%) revenues in 2030 for these molecules Vi
Slide 29: 2025-2030: maximising opportunities in strategic franchises
LEADING FROM SCIENCE 2025 - 2030: maximising opportunities in strategic franchises Allergies Vitamin D and Bone Gastro/immunomodulation Short and medium Short and medium Short and medium term term term Largest product range of a modern Best treatment for vitamin D Broader range of oral mesalazine an
Slide 30: 2025-2030: focus on adding differentiation to our portfolio
LEADING FROM SCIENCE 2025 - 2030: focus on adding differentiation to our portfolio Indication Launch expected in: 2025 2026 2027 2028 Status Bilastine ophthalmic paediatric In registration phase Bilastine 10 mg <6years In registration phase Allergies Parenteral Bilastine Registered project Bilastina
Slide 31: 2025-2030: Ophthalmology key therapeutic area
LEADING FROM SCIENCE 2025 - 2030: Ophthalmology key therapeutic area Why ophthalmology? Opportunity for Faes Farma - Building on our strengths High prevalence Suitability for the R&D&I model / 1/5 Europeans suffer from dry eye / Value contribution of incremental innovation / 1/6 people have conjunct
Slide 32: New plan 2025-2030: based on key levers for growth
New plan 2025-2030: based on 4 key levers for growth To be recognised as the best global Spanish pharmaceutical company Accelerate the Leading from Achieving commercial Promoting a positive and operational impact on our culture growth science excellence and environment / Growing organically in exist
Slide 33: Achieving commercial excellence
ACHIEVING COMMERCIAL AND OPERATIONAL EXCELLENCE Achieving commercial excellence Technology underpinning a new model of commercial excellence Commercial excellence Digitalisation Transforming the Go-To-Market model to Data infrastructure and governance project, for increase commercial effectiveness m
Slide 34: Derio: the future of Faes Farma
ACHIEVING COMMERCIAL AND OPERATIONAL EXCELLENCE Derio: the future of Faes Farma Operational excellence, manufacturing control / Industrial support to the strategic plan Forecast doubling of production volumes over the and supporting the Group's growth period / Potential for future expansion Ability
Slide 35: Lean Manufacturing philosophy in Derio
ACHIEVING COMMERCIAL AND OPERATIONAL EXCELLENCE Opera onal Excellence Growth and Efficiency Lean Manufacturing philosophy in Derio The centralisation of production in Derio, / Operational Efficiency planned for 2027, will allow Faes Farma to Process redesign for line performance optimisation increas
Slide 36: New plan 2025-2030: based on key levers for growth
New plan 2025-2030: based on 4 key levers for growth To be recognised as the best global Spanish pharmaceutical company Accelerate the Leading from Achieving commercial Promoting a positive and operational impact on our culture growth science excellence and environment / Growing organically in exist
Slide 37: To be a best place to work
PROMOTING POSITIVE IMPACT To be a "best place to work" Fostering a culture of collective growth and success / Inspiring Purpose, Values and Culture / Diversity, equality and inclusion Redefining Faes Farma's identity to inspire employees Ensuring an environment of respect, appreciation and and stren
Slide 38: Sustainability: positive impact on people and our environment
PROMOTING POSITIVE IMPACT Sustainability: positive impact on people and our environment Our strategy guarantees a culture of ethics and excellence that guides every business decision, generating a positive impact on people and the environment. We contribute directly to SDGs 2 and 3, and indirectly t
Slide 39: Capital allocation supports a promising future for Faes Farma
PROMOTING POSITIVE IMPACT Capital allocation supports a promising future for Faes Farma We reinforce the growth of Strengthening our Organic investments Reinforcement of the business and portfolio industrial reinforcement of the resources dedicated to with the industrial industrial capacities: comme
Slide 40: Key messages
Key messages / A global and consolidated business as a starting point. / Clear ambition: double revenues and EBITDA in 5 years, reaching ~€1 billion in revenues with +12-13% anual growth including M&A. / Innovation as a driver of sustainable growth: +25 M€ invested in R&D&I in 2024 and the objective
Slide 41: Close & Q&A
Close & Q&A
Slide 42: Speakers Q&A
Speakers Q&A Eduardo José Luís Alberto Juan Recoder Díaz Fernández Veiga CEO Chief International Chief Marketing and Head of Business Officer Portfolio Strategy Transformation Office Office 42
Slide 43: Disclaimer
DISCLAIMER This is a translation of the original Spanish document for informational purposes only. The original document remains the definitive and binding version. This presentation has been prepared and published by Faes Farma Group and is presented for information purposes only. This presentation